Pangaea Biotech Overview
- Founded
-
2007
- Status
-
Public
- Employees
-
59
- Stock Symbol
-
PANG
- Share Price
-
$1.82
- (As of Thursday Closing)
Pangaea Biotech General Information
Description
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Laboratory Services (Healthcare)
Stock Exchange
MAD
Primary Office
- C/Sabino Arana, 5-19
- 08028 Barcelona
- Spain
+34 935 00 00 00
Pangaea Biotech Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.82 | $1.82 | $1.54 - $2.53 | $40.8M | 22.5M | 1.91K | -$0.04 |
Pangaea Biotech Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 34,943 | 34,943 | 37,017 | 28,924 |
| Revenue | 5,442 | 5,442 | 4,673 | 3,713 |
| EBITDA | 171 | 171 | 832 | (1,917) |
| Net Income | (759) | (759) | (1,997) | (5,419) |
| Total Assets | 23,606 | 23,606 | 20,890 | 18,906 |
| Total Debt | 6,064 | 6,064 | 8,516 | 7,874 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Pangaea Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pangaea Biotech Patents
Pangaea Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3120851-A1 | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers | Withdrawn | 21-Jul-2015 | 0000000000 | 0 |
| EP-2492688-A1 | Molecular biomarkers for predicting response to antitumor treatment in lung cancer | Withdrawn | 23-Feb-2011 | 000000000000 | 00 |
| AU-2011347211-A1 | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer | Abandoned | 22-Dec-2010 | 0000000000 | |
| CA-2822474-A1 | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer | Abandoned | 22-Dec-2010 | 0000000000 | |
| US-20150038520-A1 | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer | Abandoned | 22-Dec-2010 | C12Q1/6886 |
Pangaea Biotech Executive Team (3)
Pangaea Biotech Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000ú0 00000 000é000 | Pangaea Biotech | Board Member | 000 0000 |
| 0000 0000000 00 | Pangaea Biotech | Board Member | 000 0000 |
| 000000 0ó000-00é0000 | Pangaea Biotech | Board Member | 000 0000 |
| 000000 000000 00.0 | Pangaea Biotech | Co-Founder, Chief Scientific Officer, Chairman & Member of Scientific Committee | 000 0000 |
| 00000000 00000 0 00000 00 | Pangaea Biotech | Co-Founder, Vice-President & Director, Molecular Pathology | 000 0000 |
Pangaea Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
